-
Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytren's Contracture
Thursday, June 30, 2011 - 7:06am | 176Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced three year recurrence data from the Collagenase Optimal Reduction of Dupuytren's - Long-term Evaluation of Success Study (CORDLESS) for XIAFLEX® (collagenase clostridium histolyticum) in the treatment of adult Dupuytren's contracture...
-
VIVUS Submits New Drug Application for Avanafil
Thursday, June 30, 2011 - 6:58am | 220VIVUS, Inc. (NASDAQ: VVUS) today announced that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of avanafil, its investigational drug for the treatment of erectile dysfunction (ED). The NDA submission follows the successful completion...
-
Puts Purchased on Medicis Pharmaceutical Corporation
Wednesday, June 29, 2011 - 2:50pm | 133Shares of Medicis Pharmaceutical Corporation (NYSE: MRX) are higher on the session by 0.58%, currently trading at $37.96. The stock has been moving largely higher over the past six months and is currently trading above the 50-day moving average. Options traders are buying puts on the name today....
-
Bank of America Merrill Lynch Raises Watson Pharmaceuticals PT To $74
Wednesday, June 29, 2011 - 1:06pm | 127Bank of America Merrill Lynch raised its Watson Pharmaceuticals (NYSE: WPI) price target from $67 to $74 in a research report published today. Bank of America Merrill Lynch has previously given Watson a Neutral rating. In the report, Bank of America Merrill Lynch states, "Based primarily on higher...
-
Perrigo Provides Update on Acquisition of Paddock Labs
Wednesday, June 29, 2011 - 8:56am | 272Perrigo Company (Nasdaq: PRGO) today announced that it continues to work to finalize the regulatory approvals necessary to complete the acquisition of Paddock Laboratories, Inc.. Perrigo Chairman and CEO Joseph C. Papa stated, "We are looking forward to concluding the transaction as soon as...
-
Morgan Stanley Raises Price Target On Watson Pharmaceuticals To $78
Wednesday, June 29, 2011 - 8:29am | 100According to Morgan Stanley, Watson Pharmaceuticals (NYSE: WPI) price target is raised to $78. Morgan Stanley said that it raised its ‘11E EPS 5% from $4.13 to $4.34 and its ‘12E EPS 10% from $5.21 to $5.74. “Our ‘11E-‘12E are 3% and 6% above cons' $4.23 and $5.42. We expect WPI to raise 2011...
-
Citi Maintains Hold Rating On Eli Lilly
Wednesday, June 29, 2011 - 7:56am | 82According to Citi, Eli Lilly (NYSE: LLY) will host its investment community meeting on June 30th in New York City. Citi said that the focal point of the meeting is on LLY's updated 2014 minimum guidance, which incorporates the impact of US healthcare reform, EU pricing austerity, earlier than...
-
Morgan Stanley Raises PT On Watson Pharmaceuticals To $78
Wednesday, June 29, 2011 - 6:18am | 27Morgan Stanley has raised the price target on Watson Pharmaceuticals (NYSE: WPI) from $68 to $78 and maintains its Overweight rating.
-
Stocks to Watch for 6/29/11: Fresh 52 Week Highs and Lows
Wednesday, June 29, 2011 - 4:11am | 2861Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels. The following stocks hit new 52-week highs in Tuesday's trading session: 1) CIGNA (NYSE: CI): Shares of CIGNA hit a 52-week high of $51.16 in Tuesday's...
-
Watson up on favorable ruling
Tuesday, June 28, 2011 - 6:20pm | 67The drugmaker's shares jumped 4.2% to 68.20 after a federal court agreed with Watson Pharmaceuticals' (WPI) interpretation of Endo Pharmaceuticals' (ENDP) patent claim for its pain-killing patch Lidoderm. Watson is seeking FDA approval to make a generic version of Lidoderm. In Feb., Endo sued...
-
Duncan Williams Maintains Medicis Pharmaceutical Buy, $43 PT
Tuesday, June 28, 2011 - 6:09pm | 104Duncan Williams maintained its Medicis Pharmaceutical (NYSE: MRX) Buy rating and $43 price target in a research report published today. In the report, Duncan Williams states, "(1) Medicis plans to initiate new marketing initiatives on Solodyn and Dysport in 3Q11 which are expected to drive...
-
Q&A with Aethlon Medical CEO, Jim Joyce; The Potential for the Hemopurifier® Medical Device in Cancer Immunotherapy
Tuesday, June 28, 2011 - 12:21pm | 943Point Roberts, WA - June 28, 2011 - Investorideas.com, a leader in sector stock research presents a new interview in its series of biotech Q&A's, featuring Jim Joyce, CEO of Aethlon Medical (OTCBB: AEMD), discussing how the Hemopurifier® medical device can be used in Cancer Immunotherapy...
-
Tuesday's Mid-Day Options Volume Leaders
Tuesday, June 28, 2011 - 11:26am | 85Here are today's mid-day options volume leaders… 1. Apple Inc. (NASDAQ: AAPL) 110,045 contracts, 59.0% calls, 41.0% puts 2. Bristol Myers Squibb Co. (NYSE: BMY) 62,915 contracts, 94.5% calls, 5.5% puts 3. Bank of America (NYSE: BAC) 61,112 contracts, 56.7% calls, 43.3% puts 4. Citigroup Inc. (NYSE...
-
Eli Lilly: Newly Published Study Showed Axiron Topical Solution Restored Testosterone Levels to Normal Range in Hypogonadal Men
Tuesday, June 28, 2011 - 10:45am | 357Eli Lilly and Company (NYSE: LLY) announced that a pivotal Phase III Axiron study, published on the Clinical Endocrinology website, showed that Axiron® (testosterone) topical solution CIII, when applied to the underarm, met the primary study objective to restore testosterone levels to the normal...
-
Bristol-Myers Squibb Signs New Agreement to Expand Access to Reyataz® (atazanavir sulfate) in sub-Saharan Africa and India
Tuesday, June 28, 2011 - 10:00am | 235Bristol-Myers Squibb Company (NYSE: BMY) today announced a new agreement to expand access to Reyataz® (atazanavir sulfate). The immunity-from-suit agreement signed with Matrix Laboratories Limited, a Mylan Company, enables the generic company to manufacture and sell atazanavir, as well as stavudine...